These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21185966)

  • 1. Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer.
    Bós AM; Howard BV; Beresford SA; Urban N; Tinker LF; Waters H; Bós AJ; Chlebowski R; Ennis JM
    J Am Diet Assoc; 2011 Jan; 111(1):56-66. PubMed ID: 21185966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.
    Roth JA; Etzioni R; Waters TM; Pettinger M; Rossouw JE; Anderson GL; Chlebowski RT; Manson JE; Hlatky M; Johnson KC; Ramsey SD
    Ann Intern Med; 2014 May; 160(9):594-602. PubMed ID: 24798522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
    Ito K; Elkin E; Blinder V; Keating N; Choudhry N
    Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.
    Yoon AP; Kane RL; Hutton DW; Chung KC
    JAMA Netw Open; 2020 Oct; 3(10):e2019861. PubMed ID: 33030553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Open Versus Endoscopic Carpal Tunnel Release.
    Barnes JI; Paci G; Zhuang T; Baker LC; Asch SM; Kamal RN
    J Bone Joint Surg Am; 2021 Feb; 103(4):343-355. PubMed ID: 33591684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
    Lee Y; Mozaffarian D; Sy S; Huang Y; Liu J; Wilde PE; Abrahams-Gessel S; Jardim TSV; Gaziano TA; Micha R
    PLoS Med; 2019 Mar; 16(3):e1002761. PubMed ID: 30889188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
    Dilley SE; Havrilesky LJ; Bakkum-Gamez J; Cohn DE; Michael Straughn J; Caughey AB; Rodriguez MI
    Gynecol Oncol; 2017 Aug; 146(2):373-379. PubMed ID: 28577884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
    Ward MC; Vicini F; Al-Hilli Z; Chadha M; Pierce L; Recht A; Hayman J; Thaker N; Khan AJ; Keisch M; Shah C
    Breast Cancer Res Treat; 2020 Jul; 182(2):355-365. PubMed ID: 32468336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefits and costs of tamoxifen for breast cancer prevention.
    Eckermann SD; Martin AJ; Stockler MR; Simes RJ
    Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.